Timothy Garvey, M.D., from the UAB Diabetes Research Center at the University of Alabama at Birmingham, and colleagues examined the efficacy and safety of tirzepatide versus placebo for weight management for people with obesity and type 2 diabetes in a phase 3 trial conducted in seven countries
Regular follow-ups ensure progress and safety, with adjustments made as needed
Structure's Phase 2 trial enrolled people with obesity or who are overweight and have a weight-related complication like heart disease, randomizing 61 to receive aleniglipron and 12 to receive a placebo
In other embodiments, the formulation or composition provides a therapeutically effective amount of at least one otic therapeutic agent at the site of disease with little or no detectable systemic exposure
When patients begin tirzepatide, providers often start at lower doses to minimize side effects, meaning full appetite suppression may not activate immediately
Many people find that maintaining optimal antioxidant levels helps them feel more resilient and supports a "healthy glow" from the inside out
